In a small study of men with low bone mineral density (BDM) living with HIV and taking anti-retroviral therapy, both zoledronate or denosumab were well tolerated and effective for bone mineral density of the lumbar spine and femoral neck.
Imaging of Axial Psoriatic Arthritis
The axial phenotype of psoriatic arthritis (axPsA) is an excellent example of a major controversy in rheumatology that has become the focus of attention because of the emergence of new therapies with different mechanisms of action for alleviating joint inflammation. It was first described in 1961 but, until recently, it has largely remained under the…
Axial Disease in Psoriatic Arthritis
When Moll and Wright first described the spondyloarthritides in the early 1970s, the archetype of the group was ankylosing spondylitis (AS).1 The shared clinical features of the spondyloarthritides were sacroiliitis; asymmetric large joint peripheral arthritis; psoriasis or psoriaform skin lesions, including keratoderma blennorrhagica; uveitis; and bowel inflammation. Moll and Wright described five clinical subgroups of…
New HCPCS Code Added for Anifrolumab-fnia, 1 mg
Effective for dates of service on or after April 1, the Healthcare Common Procedure Coding System (HCPCS) code J0491 is valid for billing 1 mg anifrolumab-fnia.
CVS Issues Revised Prior Authorization Forms
In response to ACR and provider concerns about administrative burden, CVS Caremark has issued a streamlined version of its prior authorization forms for many biologic drugs.
Remission Definitions in RA: Common Questions & Implications for Clinical Practice
A recent editorial provides new insights by reexamining the definitions of remission for rheumatoid arthritis and outlining concerns with the use of specific metrics for remission in clinical trials.
Risk of Adverse Outcomes Due to COVID-19 May Be Lower with TNF Inhibitor Monotherapy
Findings support the continued use of TNF inhibitor monotherapy in individuals with immune-mediated inflammatory diseases. In the study, these patients had a lower risk of hospitalization or death caused by COVID-19 than patients on other commonly prescribed treatment regimens
Anifrolumab Promising for Sustained Low Disease Activity in Patients with Lupus
ACR CONVERGENCE 2021—Using pooled data from the TULIP-1 and TULIP-2 clinical trials, researchers set out to identify whether more patients with systemic lupus erythematosus (SLE) being treated with anifrolumab achieved a low disease activity state than patients with SLE who received placebo.1-3 An analysis of the data was presented at ACR Convergence 2021 by Eric…
New Tech Provides Insights Into the Pathogenesis of Psoriatic Arthritis
The etiology of psoriatic arthritis (PsA) is poorly understood but current evidence supports an interaction between genetic and environmental factors that coalesce to promote local tissue inflammation.1-3 The pivotal cytokines that underlie the local inflammatory response in a wide range of tissues are interleukin (IL) 23, IL-17 and tumor necrosis factor (TNF).4 The central contribution…
Looking to Psoriatic Arthritis History to Disrupt Current Thinking
As the cloud moved away from the tent, Miriam’s skin suddenly became diseased, as white as snow. When Aaron turned toward her, he saw that she was diseased. —Numbers 12:10 For 29 years he [Fray Pedro de Urraca] was afflicted by … pain, suffering it at once in all the joints of his body, with…
- « Previous Page
- 1
- …
- 110
- 111
- 112
- 113
- 114
- …
- 821
- Next Page »